论文部分内容阅读
目的探讨早期应用泰舒达对帕金森患者功能障碍及临床疗效的影响。方法回顾性分析该院2013年12月—2014年12月收治的67例早期帕金森患者的临床资料,按照治疗方法分为对照组(33例)和观察组(34例),分别给予常规治疗联合左旋多巴治疗和常规治疗联合泰舒达治疗。观察二组治疗前后的改良WEBSTER帕金森病功能障碍计分变化情况以及治疗效果,并进行比较。结果经不同的治疗,观察组的各项评分均显著低于对照组(P<0.05)。观察组的治疗总有效率经统计和比较显著高于对照组,差异有统计学意义(P<0.05)。观察组的不良反应发生率经统计和比较高于对照组,但差异无统计学意义(P>0.05)。结论在常规治疗的基础上,早期应用泰舒达对帕金森患者进行治疗可以获得良好的效果。
Objective To investigate the effect of early application of testigox on Parkinson’s dysfunction and clinical efficacy. Methods The clinical data of 67 patients with early-stage Parkinson’s disease admitted from December 2013 to December 2014 in our hospital were retrospectively analyzed. According to the treatment methods, the patients were divided into control group (33 cases) and observation group (34 cases) Combination of levodopa treatment and conventional treatment combined with temsuda treatment. Observed two groups before and after treatment of modified WEBSTER Parkinson’s disease score changes and the efficacy of treatment, and compared. Results After different treatments, the scores of the observation group were significantly lower than those of the control group (P <0.05). The total effective rate of observation group was statistically higher than that of the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was statistically higher than that of the control group, but the difference was not statistically significant (P> 0.05). Conclusion On the basis of routine treatment, early application of testigox in patients with Parkinson’s disease can be treated with good results.